Opinion
Published in:
Volume 3 / Year 2014 / Issue 4
Volume 3 / Year 2014 / Issue 4
Is Australia positioned to take advantage of biosimilars?
Author(s): David Lim, DPH
Page: 184-7
Page: 184-7
Abstract: Australia currently has a small generic and biosimilar medicine industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small… Read More »
Tell me the whole story: the role of product labelling in building user confidence in biosimilars in Europe
Author(s): European Biopharmaceutical Enterprises
Page: 188-92
Page: 188-92
Abstract: The European Medicines Agency (EMA) has led the development of biosimilar regulatory pathways globally, tailoring their approach to meet the specific and scientifically determined needs of biosimilar development. However,… Read More »